RAPOPORT V. DEMENT et al. - Page 45




          Interference 102,760                                                        
          one of claims 1-13 of the Dement application as of its date of              
          original presentation.                                                      
               The Court in Ethicon Inc. v. U.S. Surgical Corp., 135                  
          F.3d 1456, 1460, 45 USPQ2d 1545, 1548 (Fed. Cir. 1998),                     
          explains conception of a joint invention as follows:                        
                    A patented invention may be the work of two                       
               or more joint inventors.  See 35 U.S.C. § 116                          
               (1994).  Because "[c]onception is the touchstone                       
               of inventorship," each joint inventor must                             
               generally contribute to the conception of the                          
               invention. . . .                                                       
                    [F]or the conception of a joint invention,                        
               each of the joint inventors need not "make the                         
               same type or amount of contribution" to the                            
               invention.  35 U.S.C. § 116.  Rather, each needs                       
               to perform only a part of the task which                               
               produces the invention. . . .                                          
                    Furthermore, a co-inventor need not make a                        
               contribution to every claim of a patent.  See 35                       
               U.S.C. § 116.  A contribution to one claim is                          
               enough. . . .  Thus, the critical question for                         
               joint conception is who conceived, as that term                        
               is used in the patent law, the subject matter of                       
               the claims at issue.                                                   
               The record establishes that both Schwimmer and Rosekind                
          conceived of specific dosages, 60 milligrams, preferably 40                 
          milligrams, and 20 milligrams, respectively, of buspirone to                
          be administered to patients for the treatment of sleep apnea.               
          These dosages fall within the broad scope of the claimed                    





                                         45                                           





Page:  Previous  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  Next 

Last modified: November 3, 2007